A Phase 1b Study of SAR650984 (Anti-CD38 mAb) in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Apr 2018
At a glance
- Drugs Isatuximab (Primary) ; Dexamethasone; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms LenCombo
- Sponsors Sanofi
- 11 Apr 2018 Planned End Date changed from 15 May 2019 to 4 Jan 2019.
- 11 Apr 2018 Planned primary completion date changed from 15 May 2019 to 4 Jan 2019.
- 21 Sep 2017 Planned End Date changed from 28 Dec 2018 to 15 May 2019.